PMID- 35862370 OWN - NLM STAT- MEDLINE DCOM- 20220725 LR - 20220725 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 7 DP - 2022 TI - Translation and performance of the Finnish Diabetes Risk Score for detecting undiagnosed diabetes and dysglycaemia in the Indonesian population. PG - e0269853 LID - 10.1371/journal.pone.0269853 [doi] LID - e0269853 AB - A diabetes risk score cannot directly be translated and applied in different populations, and its performance should be evaluated in the target population. This study aimed to translate the Finnish Diabetes Risk Score (FINDRISC) instrument and compare its performance with the modified version for detecting undiagnosed type 2 diabetes mellitus (T2DM) and dysglycaemia among the Indonesian adult population. Forward and backward translations were performed and followed by cultural adaptation. In total, 1,403 participants were recruited. The FINDRISC-Bahasa Indonesia (FINDRISC-BI) was scored according to the original FINDRISC instrument, while a Modified FINDRISC-BI was analyzed using a specific body mass index and waist circumference classification for Indonesians. The area under the receiver operating characteristic curve, sensitivity, specificity, and the optimal cut-offs of both instruments were estimated. The area under the receiver operating characteristic curve for detecting undiagnosed T2DM was 0.73 (0.67-0.78) for the FINDRISC-BI with an optimal cut-off score of >/=9 (sensitivity = 63.0%; specificity = 67.3%) and 0.72 (0.67-0.78) for the Modified FINDRISC-BI with an optimal cut-off score of >/=11 (sensitivity = 59.8%; specificity = 74.9%). The area under the receiver operating characteristic curve for detecting dysglycaemia was 0.72 (0.69-0.75) for the FINDRISC-BI instrument with an optimal cut-off score of >/=8 (sensitivity = 66.4%; specificity = 67.0%), and 0.72 (0.69-0.75) for the Modified FINDRISC-BI instrument with an optimal cut-off score >/=9 (sensitivity = 63.8%; specificity = 67.6%). The Indonesian version of the FINDRISC instrument has acceptable diagnostic accuracy for screening people with undiagnosed T2DM or dysglycaemia in Indonesia. Modifying the body mass index and waist circumference classifications in the Modified FINDRISC-BI results in a similar diagnostic accuracy; however, the Modified FINDRISC-BI has a higher optimal cut-off point than the FINDRISC-BI. People with an above optimal cut-off score are suggested to take a further blood glucose test. FAU - Rokhman, M Rifqi AU - Rokhman MR AUID- ORCID: 0000-0002-0608-3084 AD - Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. AD - Institute of Science in Healthy Ageing & healthcaRE (SHARE), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. AD - Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia. FAU - Arifin, Bustanul AU - Arifin B AUID- ORCID: 0000-0002-2303-310X AD - Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. AD - Faculty of Pharmacy, Universitas Hasanuddin, Makassar, Indonesia. AD - Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia. AD - Unit of PharmacoTherapy, Epidemiology and Economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands. FAU - Zulkarnain, Zulkarnain AU - Zulkarnain Z AD - Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia. AD - Thyroid Center, Zainoel Abidin Hospital, Banda Aceh, Indonesia. FAU - Satibi, Satibi AU - Satibi S AD - Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia. FAU - Perwitasari, Dyah Aryani AU - Perwitasari DA AUID- ORCID: 0000-0002-2638-6664 AD - Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia. FAU - Boersma, Cornelis AU - Boersma C AUID- ORCID: 0000-0002-1190-2638 AD - Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. AD - Institute of Science in Healthy Ageing & healthcaRE (SHARE), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. AD - Faculty of Management Sciences, Open University, Heerlen, The Netherlands. FAU - Postma, Maarten J AU - Postma MJ AD - Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. AD - Institute of Science in Healthy Ageing & healthcaRE (SHARE), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. AD - Unit of PharmacoTherapy, Epidemiology and Economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands. AD - Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. AD - Department of Economics, Econometrics and Finance, Faculty of Economics & Business, University of Groningen, Groningen, The Netherlands. FAU - van der Schans, Jurjen AU - van der Schans J AUID- ORCID: 0000-0001-6170-1191 AD - Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. AD - Institute of Science in Healthy Ageing & healthcaRE (SHARE), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. AD - Department of Economics, Econometrics and Finance, Faculty of Economics & Business, University of Groningen, Groningen, The Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220721 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Blood Glucose) SB - IM MH - Adult MH - Blood Glucose MH - *Diabetes Mellitus, Type 2/diagnosis/epidemiology MH - Finland MH - Humans MH - Indonesia/epidemiology MH - ROC Curve MH - Risk Factors PMC - PMC9302803 COIS- MJP reports grants and honoraria from various pharmaceutical companies, including those developing, producing and marketing diabetes drugs. However, all grants and honoraria were completely unrelated to this specific study. The other authors declare that they have no competing interests related to this specific study and topic. This does not alter our adherence to PLOS ONE policies on sharing data and materials. EDAT- 2022/07/22 06:00 MHDA- 2022/07/26 06:00 PMCR- 2022/07/21 CRDT- 2022/07/21 13:43 PHST- 2022/01/24 00:00 [received] PHST- 2022/05/29 00:00 [accepted] PHST- 2022/07/21 13:43 [entrez] PHST- 2022/07/22 06:00 [pubmed] PHST- 2022/07/26 06:00 [medline] PHST- 2022/07/21 00:00 [pmc-release] AID - PONE-D-21-35407 [pii] AID - 10.1371/journal.pone.0269853 [doi] PST - epublish SO - PLoS One. 2022 Jul 21;17(7):e0269853. doi: 10.1371/journal.pone.0269853. eCollection 2022.